´ëÇÑÀü¸³¼±ÇÐȸ 2024 KPS Annual Prostate International Meeting : 2024-03-08 |
|
´ëÇÑÀü¸³¼±ÇÐȸ 2024 KPS Annual Prostate International Meeting : 2024-03-08 ±³À°ÁÖÁ¦ : 2024 KPS Annual Prostate International Meeting ÁÖÃÖ±â°ü : ´ëÇÑÀü¸³¼±ÇÐȸ À̸ÞÀÏ : gaonpco@gaonpco.com ±³À°Á¾·ù : ºñ´¢ÀÇÇаú, ÀÇ»çÇÐ, ÀÇÇб³À° Âü¼®¿¹»óÀÎ : 150¸í Áö¿ª : ¼¿ïƯº°½Ã ¼¼ºÎ¼ö°·á : 40,000¿ø ºñ°í " - »çÀüµî·Ï: 3¸¸¿ø(Àü¹®ÀÇ, ¿¬±¸¿ø, °£È£»ç) / ¹«·á(Àü°øÀÇ, Çлý) - ÇöÀåµî·Ï: 4¸¸¿ø(Àü¹®ÀÇ, ¿¬±¸¿ø, °£È£»ç) / ¹«·á(Àü°øÀÇ,Çлý) - ¿Ü±¹ÀÎ Âü¿©ÀÚ: ¹«·á"
±³À°½Ã°£ 03¿ù 08ÀÏ SCÄÁº¥¼Ç¼¾ÅÍ 12Ãþ ¾Æ³ªÀ̽ºÈ¦ 13:10~13:30 Biomarkers and Imaging in prostate cancer diagnosis and risk stratification Behfar EHDAIE (USA)(Memorial Sloan-Kettering Cancer Center) ±³À°½Ã°£ 03¿ù 08ÀÏ SCÄÁº¥¼Ç¼¾ÅÍ 12Ãþ ¾Æ³ªÀ̽ºÈ¦ 13:30~13:50 PSMA PET imaging for prostate cancer diagnosis and selection of candidates for AS Nathan LAWRENTSCHUK(University of Melbourne) ±³À°½Ã°£ 03¿ù 08ÀÏ SCÄÁº¥¼Ç¼¾ÅÍ 12Ãþ ¾Æ³ªÀ̽ºÈ¦ 13:50~14:10 We are ready to change management based on PSMA-Yes ³²Á¾±æ(ºÎ»êÀÇ´ë) ±³À°½Ã°£ 03¿ù 08ÀÏ SCÄÁº¥¼Ç¼¾ÅÍ 12Ãþ ¾Æ³ªÀ̽ºÈ¦ 14:10~14:30 We are ready to change management based on PSMA-No ¹Ú¼ºÂù(¿ï»êÀÇ´ë) ±³À°½Ã°£ 03¿ù 08ÀÏ SCÄÁº¥¼Ç¼¾ÅÍ 12Ãþ ¾Æ³ªÀ̽ºÈ¦ 14:30~14:50 PSA screening: is it beneficial especially in asian countries? °í¿µÈÖ(¿µ³²ÀÇ´ë) ±³À°½Ã°£ 03¿ù 08ÀÏ SCÄÁº¥¼Ç¼¾ÅÍ 12Ãþ ¾Æ³ªÀ̽ºÈ¦ 14:50~15:10 Biopsy techniques: transperineal, transrectal, or avoiding biopsy Behfar EHDAIE(Memorial Sloan-Kettering Cancer Center) ±³À°½Ã°£ 03¿ù 08ÀÏ SCÄÁº¥¼Ç¼¾ÅÍ 12Ãþ ¾Æ³ªÀ̽ºÈ¦ 15:10~15:30 Individualized treatment of BPH Stavros GRAVAS (University of Cyprus ) ±³À°½Ã°£ 03¿ù 08ÀÏ SCÄÁº¥¼Ç¼¾ÅÍ 12Ãþ ¾Æ³ªÀ̽ºÈ¦ 15:30~15:50 Surgical technique and recovery of urinary incontinence after radical prostatectomy Rafael SANCHEZ-SALAS(McGill University in Montreal, Quebec) Åä·Ð 03¿ù 08ÀÏ SCÄÁº¥¼Ç¼¾ÅÍ 12Ãþ ¾Æ³ªÀ̽ºÈ¦ 15:50~16:00 Panel Discussion ÀüȲ±Õ, À̼ҿ¬, ÀÌÁ¤ÈÆ, ±Ç¼¼À±(¼º±Õ°üÀÇ´ë, ¸íÁöº´¿ø, ¼¿ïÀÇ´ë, µ¿±¹ÀÇ´ë) ÈÞ½Ä 03¿ù 08ÀÏ SCÄÁº¥¼Ç¼¾ÅÍ 12Ãþ ¾Æ³ªÀ̽ºÈ¦ 16:00~16:20 Coffee Break () ±³À°½Ã°£ 03¿ù 08ÀÏ SCÄÁº¥¼Ç¼¾ÅÍ 12Ãþ ¾Æ³ªÀ̽ºÈ¦ 16:20~16:40 Androgen receptor directed therapy in the contemporary era Daniel DANILA(Memorial Sloan-Kettering Cancer Center) ±³À°½Ã°£ 03¿ù 08ÀÏ SCÄÁº¥¼Ç¼¾ÅÍ 12Ãþ ¾Æ³ªÀ̽ºÈ¦ 16:40~17:00 Treatment options for mHSPC, advances and barriers ±èÅûó(°í½ÅÀÇ´ë) ±³À°½Ã°£ 03¿ù 08ÀÏ SCÄÁº¥¼Ç¼¾ÅÍ 12Ãþ ¾Æ³ªÀ̽ºÈ¦ 17:00~17:20 What is the optimal target for radiotherapy? Primary only, primary plus nodes, primary plus nodes plus metastases? ±èº´ÈÆ(°è¸íÀÇ´ë) ±³À°½Ã°£ 03¿ù 08ÀÏ SCÄÁº¥¼Ç¼¾ÅÍ 12Ãþ ¾Æ³ªÀ̽ºÈ¦ 17:20~17:40 Can genomic information assist in treatment decisions in the management of mHSPC? Á¤Çöö(¿øÁÖÀÇ°ú´ë) ±³À°½Ã°£ 03¿ù 08ÀÏ SCÄÁº¥¼Ç¼¾ÅÍ 12Ãþ ¾Æ³ªÀ̽ºÈ¦ 17:40~18:00 Early treatement intensification with Enzalutamide in mHSPC ±èÁ¾¿í(°í·ÁÀÇ´ë)
|
Tip. ±³À°ÀÏÁ¤Àº ±³À°±â°üÀÇ »çÁ¤¿¡ µû¶ó º¯°æµÉ ¼ö ÀÖÀ¸¹Ç·Î »çÀü¿¡ ¹Ýµå½Ã ±³À°±â°üÀ¸·Î ¹®ÀÇÇÏ¿© È®ÀÎ ¹Ù¶ø´Ï´Ù. |
|